Wiele Andrew J, Surasi Devaki Shilpa, Rao Priya, Sircar Kanishka, Su Xiaoping, Bathala Tharakeswara K, Shah Amishi Y, Jonasch Eric, Cataldo Vince D, Genovese Giannicola, Karam Jose A, Wood Christopher G, Tannir Nizar M, Msaouel Pavlos
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Nuclear Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2021 Apr 30;13(9):2170. doi: 10.3390/cancers13092170.
To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC.
We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution.
Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more prior therapies. The median progression-free survival (PFS) was 3.5 months (95% CI, 1.8-5.2). The median overall survival (OS) from bevacizumab plus erlotinib initiation was 7.3 months (95% CI, 0.73-13.8) and the median OS from diagnosis was 20.8 months (95% CI, 14.7-26.8). Bevacizumab plus erlotinib was well tolerated with no grade ≥4 adverse events and one grade 3 skin rash. Dose reduction was required in one patient (10%).
Bevacizumab plus erlotinib is clinically active and well tolerated in heavily pre-treated patients with RMC and should be considered a viable salvage strategy for this lethal disease.
评估贝伐单抗联合厄洛替尼治疗肾髓质癌（RMC）患者的疗效和安全性。
我们回顾性分析了在本机构接受贝伐单抗联合厄洛替尼治疗的RMC患者的记录。
本研究纳入了10例患者。2例患者获得部分缓解（20%），7例患者病情稳定（70%）。总体上7例患者（70%）的肿瘤负荷减轻，在接受过三种或更多先前治疗的5例患者中有3例（60%）肿瘤负荷减轻。无进展生存期（PFS）的中位数为3.5个月（95%置信区间，1.8 - 5.2）。从开始使用贝伐单抗联合厄洛替尼起的总生存期（OS）中位数为7.3个月（95%置信区间，0.73 - 13.8），从诊断起的OS中位数为20.8个月（95%置信区间，14.7 - 26.8）。贝伐单抗联合厄洛替尼耐受性良好，无≥4级不良事件，仅有一例3级皮疹。1例患者（10%）需要减量。
贝伐单抗联合厄洛替尼在经过大量前期治疗的RMC患者中具有临床活性且耐受性良好，应被视为这种致命疾病可行的挽救策略。
